Alto Neuroscience (ANRO) Net Equity Issued and Repurchased (2023)

Alto Neuroscience (ANRO) posted Net Equity Issued and Repurchased of $45.0 million for Q4 2023, up 80.0% sequentially from $25.0 million in Q1 2023.

Alto Neuroscience (ANRO) Net Equity Issued and Repurchased (2023) Analysis & Trends

Alto Neuroscience has reported Net Equity Issued and Repurchased for 1 years, with the latest figure at $45.0 million in Q4 2023.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $45.0 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $45.0 million (changed N/A YoY) and the FY2023 annual result came in at $70.0 million, changed N/A from the prior year.
Net Equity Issued and Repurchased improved to $45.0 million in Q4 2023 per ANRO's latest filing, from $25.0 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $45.0 million in Q4 2023 and troughed at $25.0 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	141.90 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Alto Neuroscience	1.13 Bn	1.13 Bn	-	-

Download Data